论文部分内容阅读
[目的]对比分析3种质子泵抑制剂雷贝拉唑、兰索拉唑、奥美拉唑在治疗反流性胃炎中的疗效。[方法]98例反流性食管炎患者,其中34例给予雷贝拉唑、33例给予兰索拉唑、32例给予奥美拉唑,3组都合用莫沙必利,观察治疗前及治疗后2、4、8周临床症状的改善情况以及治疗第8周的内镜变化情况。[结果]从第2周开始,雷贝拉唑组就显示出其比其他质子泵抑制剂更强的抑酸效果,其总有效率与其他组相比差异有统计学意义。内镜结果显示,在治疗第8周雷贝拉唑组就显示出其比其他质子泵抑制剂更强的抑酸效果,其总有效率与其他组相比差异有统计学意义。[结论]雷贝拉唑为3种质子泵抑制剂中治疗反流性胃炎疗效最好,起效最快的药物。
[Objective] To compare and analyze the efficacy of three proton pump inhibitors, rabeprazole, lansoprazole and omeprazole in the treatment of reflux gastritis. [Method] 98 cases of reflux esophagitis patients, 34 cases were given rabeprazole, 33 cases were given lansoprazole, 32 cases were given omeprazole, 3 groups were combined with mosapride, observed before and Improvement of clinical symptoms at 2, 4 and 8 weeks after treatment and endoscopic changes at 8 weeks of treatment. [Results] From the second week, the rabeprazole group showed stronger inhibitory effect than other proton pump inhibitors. The total effective rate was significantly different from other groups. Endoscopic results showed that in the eighth week of treatment, the rabeprazole group showed more inhibitory effect than other proton pump inhibitors, and its total effective rate was significantly different from other groups. [Conclusion] Rabeprazole is the best and most effective drug for the treatment of reflux gastritis in three kinds of proton pump inhibitors.